title: Sclerostin levels in CKD patients: an important, but not definitive, step on the way to clinical use.
abstract: Sclerostin, an inhibitor of the Wnt signaling pathway, inhibits bone formation. In a study of vascular biopsies of patients undergoing kidney transplantation, Qureshi et al. demonstrate that circulating sclerostin levels are associated with vascular calcification (VC). This adds to an emerging body of literature implicating sclerostin as a key link between chronic kidney disease-mineral and bone disorder and cardiovascular disease. Some confounders of this association remain, and the mechanisms by which sclerostin promotes VC have yet to be elucidated.
authors.affiliation: Department of Nephrology, Dialysis, Hypertension, Transplantation, University of Liège, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.
authors.forename: Pierre
authors.initials: P
authors.lastname: Delanaye
authors.affiliation: Department of Clinical Chemistry, University of Liège, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.
authors.forename: Etienne
authors.initials: E
authors.lastname: Cavalier
authors.affiliation: Department of Nephrology, Dialysis, Hypertension, Transplantation, University of Liège, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.
authors.forename: Antoine
authors.initials: A
authors.lastname: Bouquegneau
authors.affiliation: Department of Nephrology, Dialysis, Transplantation, Sheffield Kidney Institute, Sheffield, UK.
authors.forename: Arif
authors.initials: A
authors.lastname: Khwaja